Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT00644280
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections

Study Details

To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to observation.

Key Dates

First listed
Mar 26, 2008
Start date
Apr 30, 2008
Status verified
Jul 2022
Primary completion
Dec 31, 2010
Completion
Jan 31, 2011

Study Design

Enrollment
11 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ranibizumab
    Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
  • No Intervention: Usual care
    Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab

Primary Outcome Measure

Tube Success at 6 Months [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143-0730-

Find similar trials in San Francisco, CA

By condition
Glaucoma
By specialty
Ophthalmology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies